ATLANTA -- Plasma-derived human apolipoprotein A1 (CSL112) infusions failed to improve outcomes for acute myocardial infarction (MI) patients with multivessel coronary artery disease and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback